ScripThe number of competitive drug candidates transferring from Chinese research and development pipelines to US-based biopharmaceutical company portfolios has grown significantly during the first half of
ScripAmong Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-
In VivoChinese companies are conducting multiple clinical trials for obesity medicines, especially domestically, and ramping up the production of semaglutide generics, meaning there’s no lack of drug options
ScripJiangsu Hengrui Pharmaceuticals, China’s top drug developer by size of pipeline, is set to stage the world’s biggest new share sale by a pharmaceutical company so far in 2025 by raising up to HKD9.89b